Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q3 FY21 results · Oct–Dec 2020
Natco Pharma reported revenue from operations of ₹355.20 crore (down 26.3% from Q3 FY20) and net profit of ₹63.40 crore (down 39.3% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 355.20 | 482.20 | −26.3% | 802.20 | −55.7% |
| Other income | 30.80 | 30.80 | +0.0% | 25.70 | +19.8% |
| Total income | 386.00 | 513.00 | −24.8% | 827.90 | −53.4% |
| Profit before tax | 80.10 | 128.80 | −37.8% | 270.70 | −70.4% |
| Net profit for the period | 63.40 | 104.40 | −39.3% | 203.90 | −68.9% |
| Attributable to shareholders of the company | 62.70 | 104.50 | −40.0% | 202.40 | −69.0% |
| EPS, basic (₹) | 3.44 | 5.75 | −40.2% | 11.12 | −69.1% |
| Net margin (%) | 17.8 | 21.7 | 25.4 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 330.90 | 447.70 | −26.1% | 478.90 | −30.9% |
| Other income | 24.90 | 30.90 | −19.4% | 27.20 | −8.5% |
| Total income | 355.80 | 478.60 | −25.7% | 506.10 | −29.7% |
| Profit before tax | 70.70 | 127.30 | −44.5% | 86.50 | −18.3% |
| Net profit for the period | 54.70 | 103.60 | −47.2% | 70.90 | −22.8% |
| EPS, basic (₹) | 3.00 | 5.70 | −47.4% | 3.89 | −22.9% |
| Net margin (%) | 16.5 | 23.1 | 14.8 |
Consolidated
- Filed with BSE
- 11 Feb 2021, 16:09 IST
- Board meeting
- 11 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Feb 2021, 16:09 IST
- Board meeting
- 11 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE